Expert Opin. Drug Deliv. (2014) 11 (5): [823][824][825] I read with great interest the article by Job van der Palen et al. [1]. The article describes the comparison of a new single-dose dry powder inhaler, Elpenhaler (EH) (Elpen Pahrmaceutical Co., Inc., Greece) versus the established dry powder inhaler, Accuhaler/Diskus (DK) (GlaxoSmithKline, UK) in patients with chronic obstructive pulmonary disease (COPD) and asthma. The basic conclusion of the authors is as follows: 'With DK fewer errors were made, more patients preferred DK over EH and patients were more satisfied with DK'. It is the purpose of this letter to demonstrate that this conclusion is misleading since it is based on serious oversights of the design of the study.
concerning the necessity of proper patient training before the use of any inhalation device.
Overall, the main disagreement concerning the article of Job van Palen et al. [1] is that the design of their study incorporates a 'bias' in favor of DK.
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Author's response
We would like to respond to this letter that according to the writer has the purpose 'to demonstrate that this [our] conclusion is misleading since it is based on serious oversights of the design of the study'. The author is referring to our basic conclusion: 'With DK fewer errors were made, more patients preferred DK over EH and patients were more satisfied with DK'. The author is correct in assuming that the 'instructions of usage' were translated from English to Dutch. We would like to thank the writer of this letter for pointing out our error in not including 'visual verification of dose uptake' in our error checklist. What is not clear from the manuscript is the exact content of the instruction sheet. This was translated from English and did include the statement on 'visual verification of dose uptake'. Therefore, the patients knew that they could verify whether or not the dose had been successfully inhaled.
Below, I will summarize the consequences of our omission of adding 'visual verification of dose uptake'.
Our primary outcome was the percentage of patients making one or more critical error after reading the insert, while the secondary outcomes were: the percentage of patients making one or more critical errors after the first instruction by the trainer; the number of instructions needed to demonstrate a perfect inhalation technique; overall patient satisfaction; and inhaler preference. If one would consider visual verification of dose uptake as a critical error, then the percentage of patients making a critical error with the Elpenhaler could only go up. In the unlikely event that no patient would make this error, the difference in critical error rate would remain 17% for Diskus versus 35% for Elpenhaler (p = 0.001). Any extra patient making an error with the item 'visual verification of dose uptake' would further enlarge the difference in favor of the Diskus. The same is true for critical error rate following instruction by the trainer and the number of instructions needed.
The effect of adding the visual inspection item to the checklist will not have influenced our third secondary outcome, which is overall patient satisfaction, because this was included in the instruction sheet. The same probably holds true for our last secondary outcome, which is inhaler preference, in which the observed difference is very large, with 73.2% of patients preferring Diskus versus 26.8% preferring Elpenhaler (p < 0.001).
Furthermore, the author of the letter states: '…however, it can be questioned whether patients were really naive to DK, since----as stated in Table 2 ----disease history ranged between 3 and 13 years. In addition, 72.6% of patients suffered from COPD and fluticasone--salmeterol combination is the drug of choice for this disease'. On this topic we can be clear. All the included patients were truly naive to the Diskus. Contrary to the belief of the author, there are many patients that do not use the Diskus for the fluticasone--salmeterol combination in the Diskus.
In a further comment, the role of familiarity of the instructors with the Diskus and not the Elpenhaler was
